Common Brands Actos
Drug Class
Controlled Substance Classification
Not a controlled medication
Generic Status
Lower-cost generic available
Prescription only
Daisy Chau, PharmD
Daisy Chau, PharmD
Read More
Medically reviewed by Daisy Chau, PharmD last update on 20/12/2023


Xpovio, also known by its generic name selinexor, is a novel and innovative medication that has gained prominence in the field of oncology. Developed to address specific types of cancer, this drug operates through a unique mechanism of action, setting it apart from traditional cancer treatments.

Brief History and Development

The journey of Xpovio began in the laboratories of pharmaceutical research, where scientists worked tirelessly to identify novel therapeutic targets for cancer. The drug underwent rigorous preclinical testing, demonstrating promising results that propelled it into clinical trials. Its developmental trajectory and milestones mark it as a significant advancement in cancer therapy.

Mechanism of Action

At the core of Xpovio’s effectiveness lies its distinctive mechanism of action. The drug belongs to a class known as selective inhibitors of nuclear export (SINE), and it exerts its influence by inhibiting the nuclear export protein exportin-1 (XPO1). By doing so, Xpovio disrupts the transport of key proteins, leading to the accumulation of tumor-suppressing proteins within the nucleus of cancer cells. This disruption ultimately impedes cancer cell growth and survival.



Prescription only

Pregnancy & Lactation